NATCO pharma is a Hyderabad-based pharmaceutical company which became famous when the Indian Patent office used the WTO-TRIPS 2006 agreement to give it permission to replicate and produce a generic version of Bayer’s cancer drug Nexavar which would bring down the price of the drug by 97%. This was the first instance of a country giving a compulsory licence and led to protracted legal stand-off which finally ended in NATCO’s favour.

• All
• News

Bayer

India vs Big Pharma: Compulsory licence for leukaemia drug sought

India vs Big Pharma: Compulsory licence for leukaemia drug sought

Budget

Despite compulsory licensing, generic cancer drug too costly for the poor

Despite compulsory licensing, generic cancer drug too costly for the poor

Bayer

Glaxo patent on breast cancer drug revoked

Glaxo patent on breast cancer drug revoked

Bayer

'Compulsory licence verdict a triumph for humanity'

'Compulsory licence verdict a triumph for humanity'

Bayer

India vs Big Pharma: Bayer loses compulsory licencing verdict

Experts believe that this case will set a precedent for all future legal tangles between Big Pharma and the country as a marker of how cases pertaining to drug patents will be played out in the country.

Bayer

Novartis not optimistic about Supreme Court verdict

Novartis not optimistic about Supreme Court verdict

Bayer

Leading lawyer calls India's pharma sector 'hip and hapenning'

Leading lawyer calls India's pharma sector 'hip and hapenning'

Bayer

Govt set to hand out three more compulsory licenses for cancer drugs

Govt set to hand out three more compulsory licenses for cancer drugs

Big Pharma

Judges tell Novartis at Rs 1.2 lakh a month, drugs too expensive for them!

Judges tell Novartis at Rs 1.2 lakh a month, drugs too expensive for them!

Big Pharma

Novartis claims to have distributed free drugs worth Rs 7,500 cr

Novartis claims to have distributed free drugs worth Rs 7,500 cr

Big Pharma

SC asks Novartis to reduce drug price - again!

SC asks Novartis to reduce drug price - again!

Bayer

Intellectual property board hears Bayer vs compulsory licencing case, verdict awaited

Intellectual property board hears Bayer vs compulsory licencing case, verdict awaited

Bayer

Cancelling compulsory license won't be against public interest: Bayer

Cancelling compulsory license won't be against public interest: Bayer

Bayer

"Novartis win will have an adverse impact on the access to treatment"

"Novartis win will have an adverse impact on the access to treatment"

Bayer

Pathbreaking case - India Vs Big Pharma - in Supreme Court tomorrow

Pathbreaking case - India Vs Big Pharma - in Supreme Court tomorrow

Barack Obama

US wants India to increase cancer drug prices

US wants India to increase cancer drug prices

Bayer

Cipla to continue slashing cancer drug prices

Cipla to continue slashing cancer drug prices

Bayer

Bayer challenges 'compulsory license' ruling

Bayer challenges 'compulsory license' ruling

Bayer

India vs Big Pharma: Compulsory licence for leukaemia drug sought

India vs Big Pharma: Compulsory licence for leukaemia drug sought

Budget

Despite compulsory licensing, generic cancer drug too costly for the poor

Despite compulsory licensing, generic cancer drug too costly for the poor

Bayer

Glaxo patent on breast cancer drug revoked

Glaxo patent on breast cancer drug revoked

Bayer

'Compulsory licence verdict a triumph for humanity'

'Compulsory licence verdict a triumph for humanity'

Bayer

India vs Big Pharma: Bayer loses compulsory licencing verdict

Experts believe that this case will set a precedent for all future legal tangles between Big Pharma and the country as a marker of how cases pertaining to drug patents will be played out in the country.

Bayer

Novartis not optimistic about Supreme Court verdict

Novartis not optimistic about Supreme Court verdict

Bayer

Leading lawyer calls India's pharma sector 'hip and hapenning'

Leading lawyer calls India's pharma sector 'hip and hapenning'

Bayer

Govt set to hand out three more compulsory licenses for cancer drugs

Govt set to hand out three more compulsory licenses for cancer drugs

Big Pharma

Judges tell Novartis at Rs 1.2 lakh a month, drugs too expensive for them!

Judges tell Novartis at Rs 1.2 lakh a month, drugs too expensive for them!

Big Pharma

Novartis claims to have distributed free drugs worth Rs 7,500 cr

Novartis claims to have distributed free drugs worth Rs 7,500 cr

Big Pharma

SC asks Novartis to reduce drug price - again!

SC asks Novartis to reduce drug price - again!

Bayer

Intellectual property board hears Bayer vs compulsory licencing case, verdict awaited

Intellectual property board hears Bayer vs compulsory licencing case, verdict awaited

Bayer

Cancelling compulsory license won't be against public interest: Bayer

Cancelling compulsory license won't be against public interest: Bayer

Bayer

"Novartis win will have an adverse impact on the access to treatment"

"Novartis win will have an adverse impact on the access to treatment"

Bayer

Pathbreaking case - India Vs Big Pharma - in Supreme Court tomorrow

Pathbreaking case - India Vs Big Pharma - in Supreme Court tomorrow

Barack Obama

US wants India to increase cancer drug prices

US wants India to increase cancer drug prices

Bayer

Cipla to continue slashing cancer drug prices

Cipla to continue slashing cancer drug prices

Bayer

Bayer challenges 'compulsory license' ruling

Bayer challenges 'compulsory license' ruling

Page 1 of 2

Prev 12 Next